Khloe Kardashian Signs Up as Influencer for Biohaven Pharmaceuticals Migraine Drug

Biohaven Pharmaceuticals has landed reality TV star Khloe Kardashian as an influencer of a new migraine drug.

The KUPWTK star is working with Biohaven Pharmaceuticals to promote its newly launched migraine drug, Nurtec ODT.

“This campaign is all about patients” and Kardashian “has been very vocal about how she’s struggled with migraines since the sixth grade,” said CEO Vlad Coric in a “Mad Money” interview about the collaboration.

Kardashian, 36, is working with the drugmaker on its newly launched “Take Back Today” campaign to share information to manage the neurological condition of migraines.

“This campaign is all about patients and when we were looking for additional patient advocates, Khloe Kardashian really rose to the top because she has been very vocal about how she’s struggled with migraines since the sixth grade,” said Coric to CNBC’s Jim Cramer.

“Khloe heard about Nurtec ODT, got samples from her doctor and responded very nicely,” said Coric in the “Mad Money” interview, “and then was kind enough to agree to work with us to be a spokesperson for this campaign so that others can benefit, you know, from her experience.”

Nurtec ODT is the first of its kind to be authorized by the U.S. Food and Drug Administration for acute treatment of migraine in adults.

“For too long, I have also had to deal with the stigma that migraine is just another headache and that I should just ’get it over it,” Kardashian said. “People don’t understand how disabling migraine can be, especially when I have to cancel plans at the last minute.”

According to Coric, 85% of migraine patients are women. “And I know that that was an important part about why Khloe wanted to get involved,” he said. “She wanted to help empower other migraine sufferers and women that there’s a better treatment out there and that you don’t need to suffer, like I did, in the past with the older medication.”

Shares of Biohaven are up 40% year to date.

Disclaimer: We have no position in Biohaven Pharmaceutical Holding Co Ltd. (NYSE: BHVN) and have not been compensated for this article.